Infliximab maintenance therapy for fistulizing Crohn's disease.

Keywords

Medicine, Infliximab, Maintenance therapy, Crohn's disease, Placebo

References

• Anti-TNF therapy and malignancy - a critical review.Roger B. Cohen, Karen Dittrich — 2001
• Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group.E. Jan Irvine, Brian G. Feagan, James Rochon — 1994
• Seton treatment for perianal Crohn's fistulasKazutaka Koganei, Akira Sugita, Hirofumi Harada — 2004
• Effect of Fecal Diversion Alone on Perianal Crohn's DiseaseTakayuki Yamamoto, R N Allan, M R B Keighley — 2000
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.Filip Baert, Maja Noman, Séverine Vermeire — 2003
• The relationship between infliximab treatment and lymphoma in Crohn's disease.Stephen J. Bickston, Gary R. Lichtenstein, Kristen O. Arseneau — 1999
• [Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study].M Schneider, G. Laudage, I. Guggenmoos-Holzmann — 2008
• Diagnosis and Treatment of Perianal Fistulas in Crohn DiseaseDavid A. Schwartz, John H. Pembérton, William J. Sandborn — 2001
• Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous CyclosporineLaurence J. Egan, William J. Sandborn, William J. Tremaine — 1998
• Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.William J. Sandborn, Daniel H. Present, Kim L. Isaacs — 2003
• Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients.Annika Lapidus, Olle Bernell, G Hellers — 1998
• Endosonographic Evidence of Persistence of Crohn’s Disease-Associated Fistulas After Infliximab Treatment, Irrespective of Clinical ResponseAd A. van Bodegraven, Cornelius E. J. Sloots, R. J. F. Felt‐Bersma — 2002
• Magnetic Resonance Imaging of the Effects of Infliximab on Perianal Fistulizing Crohn's DiseaseG. Van Assche, Dirk Vanbeckevoort, Didier Bielen — 2003
• Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.S Brown, Mark H. Greene, Sharon K. Gershon — 2002
• Metronidazole therapy for Crohn's disease and associated fistulae.Julian Jakobovits, Marvin M. Schuster — 1984
• Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study.Daniel H. Present, Burton I. Korelitz, Nathaniel Wisch — 1980
• Infliximab for the treatment of fistulas in patients with Crohn's disease.Daniel H. Present, Paul Rutgeerts, Stephan Targan — 1999
• Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.William R. Best, Jack M. Becktel, John W. Singleton — 1976
• Crohn's DiseaseSéverine Vermeire, Gert Van Assche, Paul Rutgeerts — 1976
• Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous CyclosporineLaurence J. Egan — 1998

Cited by

• Recent advances in inflammatory bowel diseaseKeith Pettengell — 2009
• Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.Marina Mauro, Vladimir Radovic, David Armstrong — 2007
• Multidisciplinary and evidence-based management of fistulizing perianal Crohn's disease.Ricardo Sordo-Mejía, Wolfgang B. Gaertner — 2014
• Perianal Crohn's disease (Br J Surg 2004; 91: 801‐814)L Celaya Luria — 2004
• Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab.Nelson Zagalo — 2006
• Treatment of perianal fistula and abscess: Crohn’s and non-Crohn’sM. Rosca — 2007
• Biologic therapy in Crohn's disease: state of the artMargarida Ramires Paulos — 2008
• Immunopathological Characteristics of Cryptoglandular and Crohn's Anorectal FistulasB. Hadzhiev, Marianna Murdjeva — 2010
• Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?Raissa Ida Verinda — 2010
• Pre‐operative management is associated with low rate of post‐operative morbidity in penetrating Crohn’s diseaseTomás Fernández Robaina — 2010
• Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease.CD van Duyn, M Maarten Prins, Rmm Rob Smits — 2011
• Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costsGloria Aparicio de Castro, Pilar Zorrilla Calvo — 2011
• Treatment of inflammatory bowel disease (IBD)Orlando Fondevila — 2011
• Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center studyRichard K. Koelsch, Tong Chen, Dennis D. Schulte — 2012
• Th2-inducing cytokines IL-4 and IL-33 synergistically elicit the expression of transmembrane TNF-α on macrophages through the autocrine action of IL-6.Febrianto Kurniawan — 2012
• The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF TherapiesNelson M. Rodriguez, Leila E. Villaverde — 2013
• Tumor necrosis factor inhibitors for inflammatory bowel disease.Laurent Peyrin‐Biroulet — 2013
• Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.José María Mínguez Fernández — 2015
• Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort StudyW. Kamphuis — 2016
• Infliximab Dosing Strategies and Predicted Trough Exposure in Children with Crohn’s Disease哲郎 安尾, 知子 三垣, 智子 大橋 — 2016

Related papers

• Results of seton drainage and infliximab infusion for complex anal Crohn's disease.Masayuki Hotokezaka, Takuto Ikeda, Shuichiro Uchiyama — 2011
• Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications?Madhukar H. Trivedi, A. John Rush — 1994
• Long‐term outcome of maintenance infliximab therapy in children with Crohn's diseaseJeffrey S. Hyams, Trudy Lerer, Anne M. Griffiths — 2009
• Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders?Kenneth Evans, Terrence Sills, Glen Wunderlich — 2004
• Infliximab therapy in Crohn's disease: a pragmatic approach?David Kevans, Denise Keegan, Hugh Mulcahy — 2006
• Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.Christopher Ma, Chad Evaschesen, Grenvil Gracias — 2015
• Impact of prior irregular infliximab dosing on performance of long‐term infliximab maintenance therapy in Crohn's disease†Dan J. Stein, Ashwin N. Ananthakrishnan, Mazen Issa — 2010
• Increasing the Infliximab Dose Is Beneficial in Crohn’s Disease Patients Who Responded to a Lower Dose and RelapsedYoram Menachem, Benjamin Avidan, Alexandra Lavy — 2005
• Induction and Maintenance Infliximab Therapy for the Treatment of Crohn's Disease with Perianal Fistulas in Children: Retrospective, Multicenter Study.Barbara Iwańczak, Józef Ryżko, Piotr Jankowski — 2016
• Randomized controlled trials in maintenance of remission in Crohn's disease.R. D’Incà, R. Caccaro — 2012